JBM (Healthcare) (2161) Stock Overview
An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
2161 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
JBM (Healthcare) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$2.96 |
| 52 Week High | HK$3.43 |
| 52 Week Low | HK$0.94 |
| Beta | 0.35 |
| 1 Month Change | -3.27% |
| 3 Month Change | -8.64% |
| 1 Year Change | 205.15% |
| 3 Year Change | 289.47% |
| 5 Year Change | n/a |
| Change since IPO | 37.04% |
Recent News & Updates
Here's Why Shareholders May Want To Be Cautious With Increasing JBM (Healthcare) Limited's (HKG:2161) CEO Pay Packet
Jul 21
The Market Lifts JBM (Healthcare) Limited (HKG:2161) Shares 38% But It Can Do More
Jun 18JBM (Healthcare) Limited Just Recorded A 20% EPS Beat: Here's What Analysts Are Forecasting Next
Jun 15Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing JBM (Healthcare) Limited's (HKG:2161) CEO Pay Packet
Jul 21The Market Lifts JBM (Healthcare) Limited (HKG:2161) Shares 38% But It Can Do More
Jun 18JBM (Healthcare) Limited Just Recorded A 20% EPS Beat: Here's What Analysts Are Forecasting Next
Jun 15There's Reason For Concern Over JBM (Healthcare) Limited's (HKG:2161) Massive 28% Price Jump
May 04JBM (Healthcare) Limited (HKG:2161) Stock Rockets 35% But Many Are Still Ignoring The Company
Nov 08JBM (Healthcare)'s (HKG:2161) Earnings Are Weaker Than They Seem
Dec 20Here's Why JBM (Healthcare) (HKG:2161) Has Caught The Eye Of Investors
Nov 01JBM (Healthcare) Limited's (HKG:2161) Shares May Have Run Too Fast Too Soon
Jul 29Some Investors May Be Willing To Look Past JBM (Healthcare)'s (HKG:2161) Soft Earnings
Aug 03Estimating The Fair Value Of JBM (Healthcare) Limited (HKG:2161)
Jul 28Shareholder Returns
| 2161 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 1.0% | 6.3% | 2.9% |
| 1Y | 205.2% | 49.0% | 20.7% |
Return vs Industry: 2161 exceeded the Hong Kong Pharmaceuticals industry which returned 56.1% over the past year.
Return vs Market: 2161 exceeded the Hong Kong Market which returned 24.7% over the past year.
Price Volatility
| 2161 volatility | |
|---|---|
| 2161 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.8% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2161 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2161's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 279 | Patrick Wong | www.jbmhealthcare.com.hk |
JBM (Healthcare) Limited, an investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally. It operates through Branded Medicines, Proprietary Chinese Medicines, and Health and Wellness Products segments. The Branded Medicines segment develops, manufactures, and distributes branded medicines with chemical compounds as active ingredients.
JBM (Healthcare) Limited Fundamentals Summary
| 2161 fundamental statistics | |
|---|---|
| Market cap | HK$2.41b |
| Earnings (TTM) | HK$197.26m |
| Revenue (TTM) | HK$782.29m |
Is 2161 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2161 income statement (TTM) | |
|---|---|
| Revenue | HK$782.29m |
| Cost of Revenue | HK$368.59m |
| Gross Profit | HK$413.71m |
| Other Expenses | HK$216.45m |
| Earnings | HK$197.26m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 52.88% |
| Net Profit Margin | 25.22% |
| Debt/Equity Ratio | 12.9% |
How did 2161 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 05:29 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
JBM (Healthcare) Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mun Hon Tham | UOB Kay Hian Research Pte Ltd |
| Sunny Chen | UOB Kay Hian Research Pte Ltd |
| Kate Luang | UOB Kay Hian Research Pte Ltd |